Literature DB >> 23437911

Co-occurrence of cytomegalovirus-induced vanishing bile duct syndrome with papillary stenosis in HIV infection.

Ila Tyagi1, Amarender S Puri, Puja Sakhuja, Kaushik Majumdar, Manish Lunia, Ranjana Gondal.   

Abstract

Jaundice in patients with AIDS can be a result of diverse conditions ranging from opportunistic infections to drug-related hepatotoxicity. With the advent of antiretroviral therapy (ART), the prevalence of AIDS cholangiopathy as a cause of jaundice has decreased; on the other hand, ART-related hepatotoxicity has become one of the commonest causes of jaundice in these patients. AIDS cholangiopathy is a rare condition of extrahepatic biliary obstruction in patients with advanced HIV infection, usually due to opportunistic infections. Vanishing bile duct syndrome (VBDS) is an acquired disorder characterized by progressive destruction and loss of interlobular bile ducts causing intrahepatic cholestasis. Herein, we report co-occurrence of fatal cytomegalovirus (CMV)-induced VBDS along with papillary stenosis, as a component of AIDS cholangiopathy, which to the best of our knowledge has not been documented earlier. This is perhaps the third case of VBDS in a patient with AIDS, and the second in association with CMV infection. VBDS in AIDS has a poor outcome, and liver transplantation may be considered only in a suitable candidate.
© 2013 The Japan Society of Hepatology.

Entities:  

Year:  2013        PMID: 23437911     DOI: 10.1111/j.1872-034X.2012.01058.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  2 in total

1.  Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.

Authors:  Matthew Mason; Oyedele Adeyi; Scott Fung; Barbara-Ann Millar
Journal:  BMJ Case Rep       Date:  2014-11-28

2.  Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report.

Authors:  Zonghao Zhao; Lei Bao; Xiaolan Yu; Chuanlong Zhu; Jing Xu; Yu Wang; Ming Yin; Yi Li; Wenting Li
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.